Cargando...
Does structurally-mature dengue virion matter in vaccine preparation in post-Dengvaxia era?
The unexpectedly low vaccine efficacy of Dengvaxia®, developed by Sanofi Pasteur, and a higher risk of severe diseases after vaccination among dengue-naive children or children younger than 6 years old, have cast skepticism about the safety of dengue vaccination resulting in the suspension of school...
Gardado en:
| Publicado en: | Hum Vaccin Immunother |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Taylor & Francis
2019
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6816432/ https://ncbi.nlm.nih.gov/pubmed/31314657 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/21645515.2019.1643676 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|